Tech Transfer eNews Blog

Empire Discovery Institute partners with Novo Nordisk to launch drug development program


By Jesse Schwartz
Published: January 11th, 2022

Empire Discovery Institute (EDI), a NY-based non-profit drug development accelerator, has entered into a five-year collaborative research partnership with global pharma company Novo Nordisk.

Under the partnership, EDI and Novo Nordisk will launch LeapRx, a new program through which they will co-fund and support drug discovery and development projects from EDI’s partnering research institutions including the.University of Rochester, the University at Buffalo, and Roswell Park Comprehensive Cancer Center. Other academic research institutions not affiliated with EDI’s core labs can also apply to partner with LeapRx through their university technology transfer offices.

LeapRx will focus on projects that align with the existing drug pipelines of both EDI and Nordisk, specifically therapies for diabetes, obesity, cardiovascular disease, chronic kidney disease and rare blood disorders. The program will leverage EDI’s early-stage drug R&D expertise and Novo Nordisk’s regulatory, clinical and commercial capabilities.

“We look forward to working with our R&D collaboration partners at Novo Nordisk,” says Martin Graham, CEO of Empire Discovery Institute. “By bringing together scientific innovation, pharmaceutical industry expertise and funding, our mission is to facilitate the efficient translation of fundamental scientific discoveries into important new medicines for commercialization.”

Uli Stilz, vice president of Novo Nordisk Bio Innovation Hub, comments, “The intersection between fundamental academic research and pharmaceutical R&D is where we believe we can uncover the innovation that will lead to medicines of the future. We are excited to see what early-stage research projects we can support the development of through our collaboration with EDI and participating academic institutions.”

Source: EurekAlert!

Posted under: Tech Transfer e-News